Biotech | August 20, 2021
Enzene Biosciences obtains DCGI approval for Romiplostim biosimilar
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
This is Enzene Biosciences third biosimilar to be approved
Subscribe To Our Newsletter & Stay Updated
